CCNA2 and lung carcinoma: In this study, we demonstrated that T1 slowed the inhibition of CL1-0 lung cancer cell proliferation by decreasing the expressions of VEGF, Cyclin A, and Cyclin B protein in a dose-dependent manner (Figure 2); thus T1 warrants further development as an antiangiogenic agent in the treatment of lung cancer.